tiprankstipranks
Analyst Profile
Followed by 4 other investors
.
Olivia Brayer

Olivia Brayer

Cantor Fitzgerald
Wall Street Analyst
Ranked #5,571 out of 8,054 Analysts on TipRanks (#14,665 out of 21,594 overall experts)

Success Rate

67%
2 out of 3 Profitable Transactions

Average Return

-3.10%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Olivia Brayer's ratings since 2022 and opened each position for the duration of 1 Year:
66.67% of your transactions would have been profitable with an average return of -3.1%

Stock Rating Distribution

8Ratings
62.50% Buy
37.50% Hold
0.00% Sell
Distribution of Olivia Brayer's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Biomarin Pharmaceutical Inc.
(BMRN)
Rating Type:Buy
Dates:Jul 12, 2022 - Jan 01, 1970
Gain:8.10%
The most profitable rating made by Olivia Brayer

Olivia Brayer's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Aurinia Pharmaceuticals
May 10, 2022
Buy
Reiterated
$25.00
(203.95% Upside)
0%
-22.30%
2
Gilead Sciences
Jul 12, 2022
Hold
Initiated
$70.00
(6.12% Upside)
0.00%
1
BioMarin Pharmaceutical
Jul 12, 2022
Buy
Initiated
$110.00
(16.77% Upside)
100%
+8.10%
1
Alnylam Pharma
Jul 12, 2022
Hold
Initiated
$175.00
(-22.29% Downside)
0.00%
1
Regeneron
Jul 12, 2022
Hold
Initiated
$625.00
(-4.07% Downside)
0.00%
1
Vertex Pharmaceuticals
Jul 13, 2022
Buy
Initiated
$365.00
(20.97% Upside)
100%
+4.90%
2
List of latest recommendations made by Olivia Brayer. Click to expand and see Olivia Brayer's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More